American Society of Hirudotherapy

Breast Reconstruction Flap Salvage

FDA-cleared application: venous decompression of compromised DIEP, TRAM, and latissimus dorsi flaps in post-mastectomy reconstruction.

Tier A — FDA-cleared indicationFDA-cleared device indication: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Yes — FDA-cleared under K040187 (June 21, 2004) for medicinal leech application to relieve venous congestion in microsurgical reconstructive procedures, including breast reconstruction flaps.
What evidence exists?
This is an FDA-cleared use. Breast-specific evidence is thin and comes from case reports and small series, not controlled trials. One 2024 review of 28 patients found that leeches prevented loss of about 75 percent of breast tissue transfers, while another 2024 review of 34 patients found about 1 in 4 flaps were lost and about 1 in 4 patients developed an infection; in one hospital series, 3 of 4 flaps treated with leeches for a congestion that surgery could not correct were lost. Leeches do not replace surgery — if the issue is an artery problem or a fixable surgical clot, the surgical team must address that first.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Need for blood transfusion (about 1 in 3 patients) from cumulative blood loss over the treatment course
  • Aeromonas hydrophila infection (your team starts an antibiotic such as ciprofloxacin before the first leech)
  • Loss of the flap despite treatment if the underlying artery problem cannot be fixed
  • Allergic reaction to leech saliva (uncommon)
  • Visible bite-mark scarring on the reconstructed breast that may fade but may not disappear entirely
  • Longer hospital stay and emotional stress from a complication after an already long surgery
Who should not consider this
  • Patients on warfarin, apixaban, rivaroxaban, dabigatran, or heparin
  • Patients with hemophilia or another inherited bleeding disorder
  • Patients with anemia before therapy
  • Patients with active bloodstream infection or sepsis
  • Patients allergic to ciprofloxacin and other antibiotics covering Aeromonas
  • Patients whose flap has completely died (no salvage is possible — surgical removal is needed)
  • Patients whose flap problem is an artery issue (this requires surgical revision, not leeches)
What to ask your clinician
  • Is this an artery problem, a vein problem, or both? Leeches only help with vein problems.
  • Should I be taken back to the operating room before or instead of starting leech therapy?
  • Which antibiotic will I get for Aeromonas prevention, and for how long?
  • How often will my blood count be checked, and at what level would you transfuse?
  • How will the bite scars look once everything heals, and is there anything that helps them fade?
  • If the flap fails despite leeches, what are my options — a new flap from a different site, an implant, or no reconstruction?
  • Will my breast cancer follow-up care be affected by this complication or by the transfusions?
When to seek urgent care
  • Bleeding from any bite site soaking through more than one dressing per hour, or bleeding lasting more than 24 hours after the leech detaches
  • Increasing redness, warmth, swelling, or pus around the flap or bite sites
  • Fever above 38.0 C / 100.4 F, chills, or feeling suddenly unwell
  • Flap turning darker, colder, or harder despite leech therapy
  • Hives, swelling of the face or tongue, or any breathing difficulty

What this does NOT mean

  • It does not mean the flap is guaranteed to survive — in published breast-surgery reports about 1 in 4 leech-treated flaps were still lost (26.5 percent in one review of 34 patients), and in one small series 3 of 4 were lost; leeches cannot fix an artery problem.
  • It does not mean leeches replace surgical re-exploration — for early problems (less than 6 hours after surgery) the team will usually take you back to the operating room first.
  • It does not mean home use is safe — this is hospital therapy with antibiotics and blood-count monitoring.
  • It does not affect your cancer outcome — leech therapy is for the reconstruction, not the cancer treatment.

Clinical Profile

Category
Surgical reconstruction
ICD-10
T86.821, T87.41, N64.89, Z90.13
Safety tier
High

Evidence Summary

Free flap breast reconstruction (DIEP, TRAM, SIEA, PAP, latissimus) can be complicated by venous congestion, and leeches are used as a rescue measure when surgical correction is not possible. No controlled trial of leech therapy in breast flaps was identified. Breast-specific evidence is limited to case reports and small series: a 2024 systematic review (Rajaram et al.; 18 studies, 28 patients in total, 14 of the studies case reports) reported that leeching prevented loss of 75% of tissue transfers with a complication rate of 81%; a second 2024 systematic review (Foppiani et al.; 12 studies, 34 patients) reported flap loss in 26.5% and infection in 26.5%; and a retrospective single-centre series (Pannucci et al. 2014) found that 3 of 4 flaps treated with leeches for surgically uncorrectable venous congestion were lost. Broader evidence comes from mixed-flap experience rather than breast-specific trials: a 2012 systematic review of 277 reported clinical cases of leech therapy across plastic and reconstructive surgery found an overall success (salvage) rate of about 78%, while a 2012 retrospective series of 39 patients with venous congestion found that among 27 regional and free flaps roughly one-third were fully salvaged, one-third partially salvaged, and one-third lost. All of these figures come from uncontrolled reports, so they cannot show how many flaps would have survived without leeches. Leech therapy does not replace surgical re-exploration for arterial issues or for early venous compromise where revision of the anastomosis is feasible.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan do not write about breast reconstruction specifically: they describe venous congestion in transplanted flaps in general and list it among the indications for hirudotherapy[B1].
  • Closest to this topic are two cases that they cite (Gross, Apesos, 1992): after chest surgery, the nipple became engorged with venous blood; in both cases leeches were applied early after the operation, and the circulation was reported to have been restored[B1].
  • According to their description, the leech first sucks out the pooled blood, and then blood continues to flow from the small wound; among the main factors of the effect they also name the anticoagulant action of the leech's saliva; in this way the tissue is relieved of congestion[B1].
  • Michalsen et al. call hirudotherapy for acute venous congestion after surgery an internationally established method that can be classified as a standard treatment; according to them, controlled clinical studies are still lacking and are unlikely ever to be carried out, because leaving the patients in a study’s control group without an established treatment would be ethically untenable[B3].
  • Among the risks, Baskova and Isakhanyan name blood loss, which may require a blood transfusion, and wound infection: it often complicates this treatment and markedly lowers the chances of saving the transplanted tissue[B1].
  • Both books state that in plastic and reconstructive surgery antibiotics are prescribed together with the leeches[B1][B3].
  • If the flap receives poor arterial blood supply, leeches are contraindicated[B1].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Key Trials

  1. Nguyen MQ et al. (2012), n=39 · Microsurgery · PMID 22473683 · ASH analysis →
  2. Knobloch K et al. (2007) · Handchir Mikrochir Plast Chir · PMID 17497605 · ASH analysis →
  3. Whitaker IS et al. (2012), n=277 · Microsurgery · PMID 22407551 · ASH analysis →
  • Nguyen MQ et al. 201239
  • Whitaker IS et al. 2012277
Participants per key trial (n). Larger trials generally carry more statistical weight; case series with unspecified counts are omitted.
Study-design composition of the evidence base for Breast Reconstruction Flap Salvage3studies
  • Cohort: 1 (33%)
  • Systematic Review: 2 (67%)
Composition of the cited evidence base by study design, from strongest (meta-analysis, systematic review) to weakest (case report). A base weighted toward RCTs and reviews is more reliable.

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Total flap necrosis (non-salvageable; proceed to debridement)
  • Arterial insufficiency (must address surgically before leeching)

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.